Compare BIO-TECHNE Corp (TECH) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs United States Oil ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while United States Oil ETF trades at $127.26. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while United States Oil ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| TECH | USO | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | — |
52-Week High | $72.29 | $152.96 |
52-Week Low | $43.31 | $66.17 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
USO trades at $117.98, down 0.75% amid bearish technical signals with 13 sell indicators versus 4 buy signals. The stock faces pressure from Middle East tensions affecting oil markets, though RSI levels suggest potential oversold conditions. Recent news highlights ongoing Strait of Hormuz deadlock and declining Strategic Petroleum Reserve levels, creating volatility in energy sector valuations.
The outlook remains cautious with technical weakness and geopolitical uncertainty weighing on sentiment. Investment opportunity exists for contrarian buyers given oversold RSI levels, but risks include prolonged Middle East tensions and oil price volatility. Fundamental analysis is limited without current financial ratios available.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
